A Multicenter, Open Label, Non-randomized First-in-human Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BAY 3547926 Alone, and in Combination, in Participants With Advanced Hepatocellular Carcinoma (HCC)
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs BAY 3547926 (Primary)
- Indications Liver cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Bayer
- 13 Jan 2025 New trial record